ARDELYX, INC. Operating Lease, Payments
ARDELYX, INC. (ARDX) reported Operating Lease, Payments of $446.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- ARDELYX, INC. operating lease, payments for the quarter ending 2026-06-30 was $446.00K, a 31.18% increase year-over-year.
- ARDELYX, INC. operating lease, payments for the quarter ending 2026-03-31 was $442.00K, a 57.78% decline year-over-year.
- ARDELYX, INC. operating lease, payments for the quarter ending 2025-12-31 was $427.00K, a 68.06% decline year-over-year.
- ARDELYX, INC. operating lease, payments for the quarter ending 2025-09-30 was $279.00K, a 77.30% decline year-over-year.
- ARDELYX, INC. operating lease, payments for fiscal 2025 was $2.09M, a 57.55% decline from fiscal 2024.
- ARDELYX, INC. operating lease, payments for fiscal 2024 was $4.93M, a 10.04% increase from fiscal 2023.
- ARDELYX, INC. operating lease, payments for fiscal 2023 was $4.48M, a 4.40% increase from fiscal 2022.
- ARDELYX, INC. operating lease, payments for fiscal 2022 was $4.29M, a 24.84% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $446.00K 10-Q · filed 2026-08-06 | $888.00K 10-Q · filed 2026-08-06 | $1.31M derived: sum of 3 quarters · filed 2026-08-06 | $1.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $442.00K 10-Q · filed 2026-04-30 | $869.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.15M derived: sum of 3 quarters · filed 2026-04-30 | $1.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $706.00K derived: sum of 2 quarters · filed 2026-02-19 | $1.05M derived: sum of 3 quarters · filed 2026-08-06 | $2.09M 10-K · filed 2026-02-19 |
| 2025-09-30 | $279.00K 10-Q · filed 2025-10-30 | $619.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.67M 10-Q · filed 2025-10-30 | $3.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $340.00K 10-Q · filed 2026-08-06 | $1.39M 10-Q · filed 2026-08-06 | $2.72M derived: sum of 3 quarters · filed 2026-08-06 | $3.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-04-30 | $2.38M derived: sum of 2 quarters · filed 2026-04-30 | $3.61M derived: sum of 3 quarters · filed 2026-04-30 | $4.83M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.57M derived: sum of 2 quarters · filed 2026-02-19 | $3.79M derived: sum of 3 quarters · filed 2026-02-19 | $4.93M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.23M 10-Q · filed 2025-10-30 | $2.45M derived: sum of 2 quarters · filed 2025-10-30 | $3.59M 10-Q · filed 2025-10-30 | $4.78M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.22M 10-Q · filed 2025-08-04 | $2.39M 10-Q · filed 2025-08-04 | $3.55M derived: sum of 3 quarters · filed 2026-02-19 | $4.67M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-01 | $2.33M derived: sum of 2 quarters · filed 2026-02-19 | $3.45M derived: sum of 3 quarters · filed 2026-02-19 | $4.55M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.28M derived: sum of 2 quarters · filed 2026-02-19 | $3.38M derived: sum of 3 quarters · filed 2026-02-19 | $4.48M 10-K · filed 2026-02-19 |
| 2023-09-30 | $1.12M 10-Q · filed 2024-10-31 | $2.22M derived: sum of 2 quarters · filed 2024-10-31 | $3.32M 10-Q · filed 2024-10-31 | $4.42M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.10M 10-Q · filed 2024-08-01 | $2.20M 10-Q · filed 2024-08-01 | $3.30M derived: sum of 3 quarters · filed 2025-02-20 | $4.37M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-02 | $2.20M derived: sum of 2 quarters · filed 2025-02-20 | $3.27M derived: sum of 3 quarters · filed 2025-02-20 | $4.33M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $2.17M derived: sum of 2 quarters · filed 2025-02-20 | $3.23M derived: sum of 3 quarters · filed 2025-02-20 | $4.29M 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.07M 10-Q · filed 2023-10-31 | $2.14M derived: sum of 2 quarters · filed 2023-10-31 | $3.19M 10-Q · filed 2023-10-31 | $4.25M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.06M 10-Q · filed 2023-08-02 | $2.12M 10-Q · filed 2023-08-02 | $3.18M derived: sum of 3 quarters · filed 2024-02-22 | $4.01M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-03 | $2.11M derived: sum of 2 quarters · filed 2024-02-22 | $2.94M derived: sum of 3 quarters · filed 2024-02-22 | $3.71M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.88M derived: sum of 2 quarters · filed 2024-02-22 | $2.65M derived: sum of 3 quarters · filed 2024-02-22 | $3.44M 10-K · filed 2024-02-22 |
| 2021-09-30 | $829.00K 10-Q · filed 2022-11-03 | $1.59M derived: sum of 2 quarters · filed 2022-11-03 | $2.38M 10-Q · filed 2022-11-03 | $3.94M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $766.00K 10-Q · filed 2022-08-04 | $1.55M 10-Q · filed 2022-08-04 | $3.11M derived: sum of 3 quarters · filed 2023-03-02 | $3.88M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $1.56M 10-Q · filed 2022-05-05 | $2.34M derived: sum of 2 quarters · filed 2023-03-02 | $3.11M derived: sum of 3 quarters · filed 2023-03-02 | $3.87M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $777.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.54M derived: sum of 2 quarters · filed 2023-03-02 | $2.31M derived: sum of 3 quarters · filed 2023-03-02 | $3.06M 10-K · filed 2023-03-02 |
| 2020-09-30 | $767.00K 10-Q · filed 2021-11-12 | $1.53M derived: sum of 2 quarters · filed 2021-11-12 | $2.29M 10-Q · filed 2021-11-12 | $3.04M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $761.00K 10-Q · filed 2021-08-13 | $1.52M 10-Q · filed 2021-08-13 | $2.28M derived: sum of 3 quarters · filed 2022-02-28 | $2.94M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $760.00K 10-Q · filed 2021-05-06 | $1.51M derived: sum of 2 quarters · filed 2022-02-28 | $2.17M derived: sum of 3 quarters · filed 2022-02-28 | $2.79M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.42M derived: sum of 2 quarters · filed 2022-02-28 | $2.03M derived: sum of 3 quarters · filed 2022-02-28 | $2.65M 10-K · filed 2022-02-28 |
| 2019-09-30 | $660.00K 10-Q · filed 2020-11-05 | $1.28M derived: sum of 2 quarters · filed 2020-11-05 | $1.89M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $616.00K 10-Q · filed 2020-08-06 | $1.23M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $614.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |